Friday, March 10, 2017 6:37:27 PM
Piper Jaffray & Co. is acting as the sole book-running manager for the offering. Wedbush PacGrow is acting as a co-manager.
A registration statement relating to the securities has been filed with the Securities and Exchange Commission, but has not yet become effective. The securities may not be sold, nor may offers to buy the securities be accepted, prior to the time the registration statement becomes effective. The offering will be made only by means of a prospectus that forms a part of the registration statement. When available, copies of the prospectus relating to the offering may be obtained from: Piper Jaffray & Co. at 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, Attention: Prospectus Department, or by calling 800-747-3924, or by emailing prospectus@pjc.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc. is a medical device company with an innovative, user-centric and integrated approach to the design, development and commercialization of products for people with diabetes who use insulin. The Company manufactures and sells the t:slim X2™ Insulin Pump, the slimmest and smallest durable insulin pump currently on the market, the t:flex® Insulin Pump, the first pump designed for people with greater insulin requirements, and the t:slim G4™ Insulin Pump, the first continuous glucose monitoring-enabled pump with touchscreen simplicity. Tandem is based in San Diego, California.
t:flex and Tandem Diabetes Care are registered trademarks, and t:slim X2 and t:slim G4 are trademarks of Tandem Diabetes Care, Inc.
Forward Looking Statement
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. These forward-looking statements include statements regarding the proposed follow-on public offering, including the anticipated amount to be raised in the offering. The Company’s actual results, and the timing of events, could differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including market conditions at the time the Company conducts the proposed offering, the reaction of investors to the Company’s recently announced financial condition, results of operations and liquidity position, and the Company’s ability to satisfy closing conditions related to the proposed offering. In addition, our results may be impacted by the other risks identified in the Company’s Registration Statement on Form S-1 relating to the offering, and other documents that the Company files with the Securities and Exchange Commission. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Unless otherwise required by applicable law or the rules of the NASDAQ Stock Market, Tandem undertakes no obligation to update or review any forward-looking statement in this press release because of new information, future events or other factors.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170308006285/en/
Tandem Diabetes Care, Inc.
Susan Morrison
858-366-6900 x7005
smorrison@tandemdiabetes.com
Recent TNDM News
- Tandem t:slim X2 Insulin Pump Now Compatible with Lyumjev Ultra-rapid Acting Insulin in European Union • Business Wire • 09/19/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/18/2024 09:06:21 PM
- Tandem Diabetes Care Announces Upcoming Conference Participation • Business Wire • 08/26/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/20/2024 12:31:52 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/20/2024 12:31:41 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/20/2024 12:31:21 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/20/2024 12:31:10 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/20/2024 12:31:00 AM
- Tandem Diabetes Care to Release Updated iOS t:connect Mobile App for t:slim X2 Insulin Pump Users Impacted by March 2024 Nationwide Recall • Business Wire • 08/19/2024 10:30:00 PM
- Tandem Diabetes Care Provides Update on March 2024 Nationwide Recall of t:connect Mobile App for iOS Devices • Business Wire • 08/12/2024 08:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/09/2024 08:52:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/01/2024 08:11:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 08:07:59 PM
- Tandem Diabetes Care Announces Second Quarter 2024 Financial Results and Increases Full Year 2024 Sales Guidance • Business Wire • 08/01/2024 08:05:00 PM
- Tandem Diabetes Care Announces Upcoming Conference Presentation • Business Wire • 07/30/2024 08:05:00 PM
- Tandem Diabetes Care and Dexcom Announce the t:slim X2 Insulin Pump with Dexcom G7 CGM Compatibility is Authorized for Sale by Health Canada • Business Wire • 07/29/2024 01:00:00 PM
- Tandem Diabetes Care et Dexcom annoncent que la pompe à insuline t:slim X2 compatible avec le système de SGC Dexcom G7 est autorisée à la vente par Santé Canada • Business Wire • 07/29/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 08:16:51 PM
- Tandem Diabetes Care to Announce Second Quarter 2024 Financial Results on August 1, 2024 • Business Wire • 07/11/2024 08:05:00 PM
- Tandem Mobi Improves Quality of Life for People Living With Type 1 Diabetes in New Data Shared at American Diabetes Association Scientific Sessions • Business Wire • 06/22/2024 03:00:00 PM
- Tandem Diabetes Care Appoints Jean-Claude Kyrillos as Chief Operating Officer • Business Wire • 06/20/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/18/2024 08:31:22 PM
- Tandem Diabetes Care to Present New Early User Insights on the Tandem Mobi System at the American Diabetes Association’s 84th Scientific Sessions • Business Wire • 06/18/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/13/2024 08:10:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/12/2024 09:39:07 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM